XGN Exagen Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: XGN

Price (delayed)

$8.55

Market cap

$207.13M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.81

Enterprise value

$210.19M

?
Relative Growth: Rel. Growth: 59
Relative Strength: Rel. Strength: 96
Relative Valuation: Rel. Valuation: 17
Relative Profitability: Rel. Profitability: 22

Exagen Inc. is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, Calif., Exagen’s mission is ...

Highlights
Exagen's revenue has increased by 21% YoY and by 4% from the previous quarter
The company's gross profit rose by 19% YoY and by 4.6% QoQ
The company's net income fell by 11% YoY but it rose by 6% QoQ
Exagen's equity has decreased by 42% YoY and by 15% from the previous quarter
XGN's quick ratio is down by 36% year-on-year and by 7% since the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://avisetest.com
Peers: OPCH PNTG

Key stats

What are the main financial stats of XGN

XGN stock price

How has the Exagen stock price performed over time
Intraday
-2.17%
1 week
9.9%
1 month
7.95%
1 year
-13.81%
YTD
40.63%
QTD
83.87%

Financial performance

How have Exagen's revenue and profit performed over time
Revenue
$71.12M
Gross profit
$41.7M
Operating income
-$13.21M
Net income
-$18.92M
Gross margin
58.6%
Net margin
-26.6%
The operating margin has grown by 22% YoY and by 10% from the previous quarter
Exagen's revenue has increased by 21% YoY and by 4% from the previous quarter
The company's gross profit rose by 19% YoY and by 4.6% QoQ
The company's net income fell by 11% YoY but it rose by 6% QoQ

Price vs fundamentals

How does XGN's price correlate with its fundamentals

Growth

What is Exagen's growth rate over time

Valuation

What is Exagen stock price valuation
P/E
N/A
P/B
16.91
P/S
2.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.96
The EPS has grown by 9% from the previous quarter and by 9% YoY
XGN's price to book (P/B) is 94% higher than its last 4 quarters average of 8.9
Exagen's equity has decreased by 42% YoY and by 15% from the previous quarter
The P/S is 75% more than the 5-year quarterly average of 1.7 and 41% more than the last 4 quarters average of 2.1
Exagen's revenue has increased by 21% YoY and by 4% from the previous quarter

Efficiency

How efficient is Exagen business performance
The ROS has grown by 20% YoY and by 12% from the previous quarter
The company's return on invested capital rose by 13% YoY and by 7% QoQ
The company's return on equity rose by 11% YoY but it fell by 7% QoQ
Exagen's return on assets has increased by 7% YoY and by 3.2% QoQ

Dividends

What is XGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XGN.

Financial health

How did Exagen financials performed over time
The total assets is 31% greater than the total liabilities
XGN's quick ratio is down by 36% year-on-year and by 7% since the previous quarter
Exagen's current ratio has decreased by 36% YoY and by 8% from the previous quarter
XGN's debt is 126% greater than its equity
The debt to equity has soared by 88% YoY and by 20% from the previous quarter
Exagen's equity has decreased by 42% YoY and by 15% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.